A Phase 1 interventional study of Tacrolimus and Cyclosporin in Hyperkalaemia, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-05.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Hyperkalemia by AstraZeneca — 2 open to participants now, 3 under way, 1 of them phase 3. Hyperkalemia · AstraZeneca.
Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 21st largest by enrollment of the 25 interventional ones that give a count, is one of 9 that started in 2021, is one of 2 in phase 1, and was the 25th registered.
134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.
Browse Hyperkalemia studies →2 of the 39 studies in Hyperkalemia by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in United States, Brazil, Canada and 10 more countries
Ages 0–18
By country, each count listing its studies:
Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 14 · Phase 4 5
First in 2011; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 88 across 103 interventional studies indexed under Hyperkalemia.
Median enrollment 150 across the 25 interventional studies, 476 across the 14 observational. Of the 36 that completed or were terminated, 22 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
1 of the studies in Hyperkalemia by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07944378AstraZenecaA Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Hyperkalemia by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be an open-label, randomised sequence, 2-period, 2-cohort, 2-treatment in each cohort, cross-over study in healthy subjects (males and females of non-childbearing potential), performed at a single study centre.
The study will comprise:
Two treatment periods:
Subjects will be assigned to either Cohort 1 (tacrolimus) or to Cohort 2 (cyclosporin). Each cohort will have 2 treatment periods. Subjects in each cohort will be randomly assigned to one of 2 treatment sequences (AB\|BA or CD\|DC) where,
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in Cohort 1 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: tacrolimus alone (treatment A) followed by the combination treatment of tacrolimus and SZC (treatment B) or vice versa.
Drug: Tacrolimus · Drug: Sodium Zirconium Cyclosilicate
Subjects in Cohort 2 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: cyclosporin alone (treatment C) followed by the combination treatment of cyclosporin and SZC (treatment D) or vice versa.
Drug: Cyclosporin · Drug: Sodium Zirconium Cyclosilicate
Each subject in this cohort will receive a single dose of oral capsules of tacrolimus on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
Each subject will receive a single dose of oral capsules of cyclosporin on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
Each subject will receive single oral doses of SZC with tacrolimus (cohort 1) or cyclosporin (cohort 2) under fasted conditions. The doses will be administered after an overnight fast of at least 12 hours.
Maximum Observed Concentration (Cmax)
Effect of co-administered SZC on the Cmax of tacrolimus and cyclosporin in healthy participants was determined.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Area Under Concentration-time Curve From Time Zero to Infinity (AUCinf)
Effect of co-administered SZC on the AUCinf of tacrolimus and cyclosporin in healthy participants was determined.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)
Effect of co-administered SZC on the AUClast of tacrolimus and cyclosporin in healthy participants was determined.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Time to Reach Maximum Observed Concentration Following Drug Administration (Tmax)
Effect of co-administered SZC on the tmax of tacrolimus and cyclosporin in healthy participants was determined.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)
Effect of co-administered SZC on the t½λz of tacrolimus and cyclosporin in healthy participants was determined.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Number of Participants With Adverse Events (AEs) and Serious AEs
Safety and tolerability of co-administration of SZC and tacrolimus/cyclosporin as compared to tacrolimus/cyclosporin alone was assessed.
Time frame: From the time of IMP administration (Day 1) to Follow-up/Early Termination Visit (7-10 days after last IMP administration) [up to 4 weeks]
The study was conducted at a single study centre (Berlin, Germany) between 30 March 2021 to 16 September 2021.
| Milestone | Cohort 1 (Tacrolimus): Treatment A, Then Treatment B | Cohort 1 (Tacrolimus): Treatment B, Then Treatment A | Cohort 2 (Cyclosporin): Treatment C, Then Treatment D | Cohort 2 (Cyclosporin): Treatment D, Then Treatment C |
|---|---|---|---|---|
| Started | 16 | 15 | 16 | 15 |
| Completed | 16 | 15 | 16 | 15 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 (Tacrolimus): Treatment A, Then Treatment B | Cohort 1 (Tacrolimus): Treatment B, Then Treatment A | Cohort 2 (Cyclosporin): Treatment C, Then Treatment D | Cohort 2 (Cyclosporin): Treatment D, Then Treatment C |
|---|---|---|---|---|
| Started | 16 | 15 | 16 | 15 |
| Completed | 16 | 15 | 16 | 15 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 (Tacrolimus): Treatment A, Then Treatment B | Cohort 1 (Tacrolimus): Treatment B, Then Treatment A | Cohort 2 (Cyclosporin): Treatment C, Then Treatment D | Cohort 2 (Cyclosporin): Treatment D, Then Treatment C |
|---|---|---|---|---|
| Started | 16 | 15 | 16 | 15 |
| Completed | 15 | 15 | 14 | 15 |
| Not completed | 1 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Participant decided to discontinue further participation | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
Effect of co-administered SZC on the Cmax of tacrolimus and cyclosporin in healthy participants was determined.
| Picogram/milliliter (pg/ml) | Treatment A: Tacrolimus (5 mg) | Treatment B: Tacrolimus (5 mg) and SZC (15 g) | Treatment C: Cyclosporin (100 mg) | Treatment D: Cyclosporin (100 mg) and SZC (15 g) |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 27140 ± 37.61 | 19350 ± 35.88 | 593.6 ± 19.54 | 608.1 ± 25.28 |
Effect of co-administered SZC on the AUCinf of tacrolimus and cyclosporin in healthy participants was determined.
| Picogram.hour/milliliter | Treatment A: Tacrolimus (5 mg) | Treatment B: Tacrolimus (5 mg) and SZC (15 g) | Treatment C: Cyclosporin (100 mg) | Treatment D: Cyclosporin (100 mg) and SZC (15 g) |
|---|---|---|---|---|
| Area Under Concentration-time Curve From Time Zero to Infinity (AUCinf) | 267900 ± 50.20 | 171700 ± 48.95 | 1884 ± 25.90 | 1810 ± 23.91 |
Effect of co-administered SZC on the AUClast of tacrolimus and cyclosporin in healthy participants was determined.
| Picogram.hour/milliliter | Treatment A: Tacrolimus (5 mg) | Treatment B: Tacrolimus (5 mg) and SZC (15 g) | Treatment C: Cyclosporin (100 mg) | Treatment D: Cyclosporin (100 mg) and SZC (15 g) |
|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) | 240800 ± 50.79 | 159000 ± 51.13 | 1792 ± 26.46 | 1718 ± 24.39 |
Effect of co-administered SZC on the tmax of tacrolimus and cyclosporin in healthy participants was determined.
| hour | Treatment A: Tacrolimus (5 mg) | Treatment B: Tacrolimus (5 mg) and SZC (15 g) | Treatment C: Cyclosporin (100 mg) | Treatment D: Cyclosporin (100 mg) and SZC (15 g) |
|---|---|---|---|---|
| Time to Reach Maximum Observed Concentration Following Drug Administration (Tmax) | 1.75 (1.00 to 3.00) | 1.50 (0.75 to 3.00) | 1.50 (0.75 to 2.50) | 1.25 (0.98 to 2.52) |
Effect of co-administered SZC on the t½λz of tacrolimus and cyclosporin in healthy participants was determined.
| hour | Treatment A: Tacrolimus (5 mg) | Treatment B: Tacrolimus (5 mg) and SZC (15 g) | Treatment C: Cyclosporin (100 mg) | Treatment D: Cyclosporin (100 mg) and SZC (15 g) |
|---|---|---|---|---|
| Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) | 33.59 ± 18.72 | 33.31 ± 22.27 | 9.223 ± 32.78 | 8.647 ± 31.12 |
Safety and tolerability of co-administration of SZC and tacrolimus/cyclosporin as compared to tacrolimus/cyclosporin alone was assessed.
| Participants | Treatment A: Tacrolimus (5 mg) | Treatment B: Tacrolimus (5 mg) and SZC (15 g) | Treatment C: Cyclosporin (100 mg) | Treatment D: Cyclosporin (100 mg) and SZC (15 g) |
|---|---|---|---|---|
| Any AE | 7 | 13 | 8 | 7 |
| Any AE with outcome = death | 0 | 0 | 0 | 0 |
| Any SAE (including events with outcome = death) | 0 | 0 | 0 | 0 |
| Any AE leading to discontinuation of IMP | 0 | 0 | 1 | 0 |
| Any AE leading to withdrawal from study | 0 | 0 | 1 | 0 |
Collected over From the time of IMP administration (Day 1) to Follow-up/Early Termination Visit (7-10 days after last IMP administration) [up to 4 weeks]. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Tacrolimus (5 mg) | 0/31 (0%) | 0/31 (0%) | 7/31 (22.6%) |
| Treatment B: Tacrolimus (5 mg) and SZC (15 g) | 0/30 (0%) | 0/30 (0%) | 13/30 (43.3%) |
| Treatment C: Cyclosporin (100 mg) | 0/31 (0%) | 0/31 (0%) | 8/31 (25.8%) |
| Treatment D: Cyclosporin (100 mg) and SZC (15 g) | 0/29 (0%) | 0/29 (0%) | 7/29 (24.1%) |
| Event | Treatment A: Tacrolimus (5 mg) | Treatment B: Tacrolimus (5 mg) and SZC (15 g) | Treatment C: Cyclosporin (100 mg) | Treatment D: Cyclosporin (100 mg) and SZC (15 g) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 3/31 | 4/30 | 1/31 | 2/29 |
| DysphagiaGastrointestinal disorders | 0/31 | 0/30 | 0/31 | 1/29 |
| HaematocheziaGastrointestinal disorders | 0/31 | 0/30 | 1/31 | 1/29 |
| Back painMusculoskeletal and connective tissue disorders | 0/31 | 0/30 | 0/31 | 1/29 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/31 | 0/30 | 0/31 | 1/29 |
| Catheter site painGeneral disorders | 0/31 | 0/30 | 0/31 | 1/29 |
| FatigueGeneral disorders | 0/31 | 0/30 | 0/31 | 1/29 |
| Ligament sprainInjury, poisoning and procedural complications | 0/31 | 0/30 | 0/31 | 1/29 |
| NasopharyngitisInfections and infestations | 0/31 | 1/30 | 1/31 | 0/29 |
| RhinitisInfections and infestations | 0/31 | 1/30 | 0/31 | 0/29 |
The randomised set consisted of all participants randomised into the study.
| Age, Continuous(years) | Cohort 1 (Tacrolimus): Treatment A, Then Treatment B | Cohort 1 (Tacrolimus): Treatment B, Then Treatment A | Cohort 2 (Cyclosporin): Treatment C, Then Treatment D | Cohort 2 (Cyclosporin): Treatment D, Then Treatment C | Total |
|---|---|---|---|---|---|
| Cohort 1 (Tacrolimus) | 38.3 ± 8.9 | 37.1 ± 9.6 | — | — | 37.7 ± 9.1 |
| Cohort 2 (Cyclosporin) | — | — | 33.2 ± 9.0 | 30.9 ± 8.3 | 32.1 ± 8.6 |
| Age, Customized(Participants) | Cohort 1 (Tacrolimus): Treatment A, Then Treatment B | Cohort 1 (Tacrolimus): Treatment B, Then Treatment A | Cohort 2 (Cyclosporin): Treatment C, Then Treatment D | Cohort 2 (Cyclosporin): Treatment D, Then Treatment C | Total |
|---|---|---|---|---|---|
| 18 - 50 years | 16 | 15 | 16 | 15 | 62 |
| 51 years and older | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1 (Tacrolimus): Treatment A, Then Treatment B | Cohort 1 (Tacrolimus): Treatment B, Then Treatment A | Cohort 2 (Cyclosporin): Treatment C, Then Treatment D | Cohort 2 (Cyclosporin): Treatment D, Then Treatment C | Total |
|---|---|---|---|---|---|
| Female | 1 | 2 | 0 | 0 | 3 |
| Male | 15 | 13 | 16 | 15 | 59 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 (Tacrolimus): Treatment A, Then Treatment B | Cohort 1 (Tacrolimus): Treatment B, Then Treatment A | Cohort 2 (Cyclosporin): Treatment C, Then Treatment D | Cohort 2 (Cyclosporin): Treatment D, Then Treatment C | Total |
|---|---|---|---|---|---|
| White | 14 | 15 | 12 | 13 | 54 |
| Black or African American | 0 | 0 | 2 | 0 | 2 |
| Asian | 1 | 0 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Other | 1 | 0 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 (Tacrolimus): Treatment A, Then Treatment B | Cohort 1 (Tacrolimus): Treatment B, Then Treatment A | Cohort 2 (Cyclosporin): Treatment C, Then Treatment D | Cohort 2 (Cyclosporin): Treatment D, Then Treatment C | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 16 | 15 | 15 | 15 | 61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Mar 2021 to primary completion in Sep 2021, 5 months.
Results were first posted in Apr 2024, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tacrolimus · Cyclosporine · Sodium zirconium cyclosilicate